The chief executive of Pfizer Inc. said the company is expecting to submit data from late-stage trials of its COVID-19 vaccine in 5- to 11-year-old children to the U.S. Food and Drug Administration within days, raising hopes that another key patient group will soon be eligible for shots. Albert Bourla said on ABC’s “This Week” on Sunday that if the FDA authorizes the vaccine’s use for this demographic, Pfizer PFE, -0.53% and German partner BioNTech BNTX, -6.66% will be ready to produce a vaccine aimed at children. “It is a different formulation,” Bourla said. “It’s one-third of the dose that we are giving to the rest of the population.” Last week, the two companies said a study found that the lower dose was safe and effective in younger children. The news comes as children have returned to in-person classrooms with only those 12 and older eligible for vaccination.
admin 17804 posts 1 comments